AU Patent

AU2020286311C1 — Compositions and methods for inhibiting expression of the ALAS1 gene

Assigned to Icahn School of Medicine at Mount Sinai · Expires 2025-01-23 · 1y expired

What this patent protects

!"# $ % & $ ' %!"#& ()()(*+,----./0() ()

USPTO Abstract

!"# $ % & $ ' %!"#& ()()(*+,----./0() ()

Drugs covered by this patent

givosiran-sodium (GIVOSIRAN SODIUM)

Patent Metadata

Patent number: AU2020286311C1
Jurisdiction: AU
Classification: —
Expires: 2025-01-23
Drug substance claim: No
Drug product claim: No
Assignee: Icahn School of Medicine at Mount Sinai
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.